Arvinas To Present Biomarker Data From Phase 1 Clinical Trial Of ARV-102 In Participants With Parkinson’s Disease At 2026 International Congress Of Parkinson’s Disease And Movement Disorders

Arvinas, Inc. (NASDAQ: ARVN) announced that it will present novel biomarker data from its Phase 1 clinical trial of ARV-102 for Parkinson’s disease at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, Korea, from October 4-8, 2026. ARV-102 is an investigational PROTAC degrader designed to target LRRK2, a protein associated with Parkinson’s disease.